Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (2639)	12/7/2010 5:38:59 PM
From: DewDiligence_on_SI	Read Replies (1) \| Respond to of 3027

>My problem with this FOB concept is that there is still not much of a pathway to approval, and I don't expect the FDA to get too specific about that until middle of next year, at best. So why move forward in this way now?< There’s enough regulatory specificity on US FoB’s for MNTA to begin serious development work—see siliconinvestor.com . Indeed, MNTA has already told investors on more than one occasion that the recently enacted legislation provided the impetus for MNTA to move forward aggressively with its FoB program(s). >So why move forward in this way now? There would be plenty of dough by the time there is some regulatory way clear to proceed.< What additional clarity would be worth waiting for? I think you’re way off base here. Regards, Dew